Lopid Patent Term Restoration and Fairness Act of 1987: Hearing Before the Subcommittee on Courts, Civil Liberties, and the Administration of Justice of the Committee on the Judiciary, House of Representatives, One Hundredth Congress, First Session, October 8, 1987, Volume 4U.S. Government Printing Office, 1988 - 350 pages |
From inside the book
Results 1-5 of 80
Page 8
... type must be examined on a case - by - case basis , and , if granted , such ex- tensions should be so narrowly drawn so as to be limited to one case under consideration and only granted under meritorious cir- cumstances . Thank you , Mr ...
... type must be examined on a case - by - case basis , and , if granted , such ex- tensions should be so narrowly drawn so as to be limited to one case under consideration and only granted under meritorious cir- cumstances . Thank you , Mr ...
Page 32
... type of situation that Public Law 98-417 was designed to remedy . It is an injustice that that law was intended to remedy , particularly where the expenses and the investment are as heavy as they apparently are in the case of Lopid ...
... type of situation that Public Law 98-417 was designed to remedy . It is an injustice that that law was intended to remedy , particularly where the expenses and the investment are as heavy as they apparently are in the case of Lopid ...
Page 33
... type that have found themselves in this situation that might have an equitable claim but apparently are not given relief by the Patent Extension Act ? Mr. TEGTMEYER . Let me start again with the premise that our po- sition is that ...
... type that have found themselves in this situation that might have an equitable claim but apparently are not given relief by the Patent Extension Act ? Mr. TEGTMEYER . Let me start again with the premise that our po- sition is that ...
Page 34
... type of guidance to us . Mr. KASTENMEIER . I appreciate the response . In respect , of course , it is not altogether that helpful . But I appreciate why you have to give that response to say you would not have that informa- tion . Our ...
... type of guidance to us . Mr. KASTENMEIER . I appreciate the response . In respect , of course , it is not altogether that helpful . But I appreciate why you have to give that response to say you would not have that informa- tion . Our ...
Page 35
... , it is a state - by - state case . It would depend on the laws , and this type of switching is seen as sometimes mandatory requirements within states unless the physicians did not sign off . Mr. MORRISON . Did you say you do not- Dr. 35.
... , it is a state - by - state case . It would depend on the laws , and this type of switching is seen as sometimes mandatory requirements within states unless the physicians did not sign off . Mr. MORRISON . Did you say you do not- Dr. 35.
Other editions - View all
Common terms and phrases
apolipoprotein Association atherosclerosis baseline bill blood Capsules cardiovascular cent Chairman changes cholesterol cholesterol levels cholestyramine clofibrate Committee concentrations coronary heart disease decrease diabetic diet dose Drug Administration dyslipidaemic effect of gemfibrozil elevated fatty acid composition FDA approval Finland follow-up Food and Drug Framingham gemfibrozil treatment glucose HDL-cholesterol Health heart attacks Helsinki Heart Study hypercholesterolaemia hypertension incidence increase ischaemic heart disease Journal KASTENMEIER Kaukola laboratory legislation lipid lowering Lipid Research Clinics lipid-lowering lipoprotein cholesterol lipoprotein lipase lipoprotein lipase activity Lithell long-term Lopid Lopid patent low density lipoprotein LRC-CPPT male Manninen market exclusivity metabolism mmol/l mortality myocardial infarction Parke-Davis patent extension patent term extension patients pharmaceutical Phase IV study placebo Primary Prevention Trial ratio reduction regulatory risk factors Royal Society safety serum cholesterol serum lipid significant Society of Medicine Subcommittee Table Term Restoration Act therapy treatment groups triglycerides Vessby VLDL Warner-Lambert Waxman-Hatch
Popular passages
Page 113 - A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity, J.
Page 113 - Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
Page 291 - Kagan A.: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men.
Page 73 - I am a partner in the Washington, DC law firm of Covington & Burling. I have been asked to present testimony on patent term restoration.
Page 341 - Five-year findings of the Hypertension Detection and Followup Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.
Page 244 - For the purposes of paragraph (2)(B), the term "due diligence" means that degree of attention, continuous directed effort, and timeliness as may reasonably be expected from, and are ordinarily exercised by, a person during a regulatory review period.
Page 67 - HL-07182 from the National Heart, Lung and Blood Institute of the National Institutes of Health, and by the American Heart Association, Indiana Affiliate, Inc.
Page 8 - Mr. BOUCHER. Thank you very much, Mr. Chairman. I want to commend you...